Sanofi: European Commission Grants Conditional Marketing Authorisation For Rezurock

The European Commission granted conditional marketing authorisation for Rezurock (belumosudil) to treat chronic graft-versus-host disease in adults and in children aged 12+ with body weight ≥40 kg. The approval enables Sanofi to commercialize the drug across the EU and strengthens its specialty care/hematology portfolio. The news is a constructive, company-specific catalyst likely to have a modest positive impact on Sanofi's revenue prospects for this indication.

Analysis

The European Commission granted conditional marketing authorisation for Rezurock (belumosudil) to treat chronic graft-versus-host disease in adults and in children aged 12+ with body weight ≥40 kg. The approval enables Sanofi to commercialize the drug across the EU and strengthens its specialty care/hematology portfolio. The news is a constructive, company-specific catalyst likely to have a modest positive impact on Sanofi's revenue prospects for this indication.